Fundraising Fox
/Companies
Sign in

Agomab Therapeutics

Antwerp, BE · Founded 2017 · 74 employees on LinkedIn · 11 known investors

Find your way into Agomab Therapeutics

Sign up to see every warm intro you have to Agomab Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Agomab Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.

BiotechHealthtechMedical Devices

Founders & leadership

TKTim Knotnerus
Tim KnotnerusChief Executive OfficerTim Knotnerus is CEO of Agomab Therapeutics, a clinical-stage biopharmaceutical company developing therapies for fibro-inflammatory and fibrotic diseases.

Investors · 11

AdBio partnerslisted by AdBio partnersParis

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Andera Partnerslisted by Andera PartnersParis

How we know: Andera Partners's portfolio page · Not right? Tell us

Asabys Partnerslisted by Asabys PartnersBarcelona

How we know: Asabys Partners's portfolio page · funding news · fiercebiotech.com · the VCSheet dataset · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · pharmaceutical-technology.com · open dataset · 5k.vc investor directory · Not right? Tell us

Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya

How we know: Pontifax Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us

V-Bio Ventureslisted by V-Bio VenturesGhent · $270K – $2.2M
Fidelity InvestmentsreportedBoston

How we know: pharmaceutical-technology.com · Not right? Tell us

Also in the syndicate · 3

Dawn BiopharmaPfizerleadWalleye Capital

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

AdimabAdimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system. The company partners with biopharma firms to accelerate the development of transformative protein therapeutics from discovery through clinical progression.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
EquityZenEquityZen operates an online marketplace that gives accredited individual investors access to shares in late-stage private companies through secondary market transactions. Now part of Morgan Stanley, the platform provides private market data, offering documents, and guided investment processes for buying and selling pre-IPO equity.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as Agomab Therapeutics.

Frequently asked questions

What does Agomab Therapeutics do?
Agomab is a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibro-inflammatory and fibrotic diseases with high unmet medical need. Its product candidates target established biological pathways using organ-restricted approaches to resolve fibro-inflammation and restore organ function.
Who are Agomab Therapeutics's investors?
Agomab Therapeutics's investors include EQT Life Sciences, AdBio partners, Andera Partners, Asabys Partners, Canaan Partners, Pontifax Venture Capital, V-Bio Ventures, Fidelity Investments.
Where is Agomab Therapeutics headquartered?
Agomab Therapeutics is headquartered in Antwerp, BE.